Monopar Therapeutics, Inc. (MNPR)
112.65
-1.73
(-1.51%)
USD |
NASDAQ |
Sep 09, 16:00
112.65
0.00 (0.00%)
After-Hours: 16:48
Monopar Therapeutics Total Assets (Quarterly) : 134.98M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 134.98M |
| March 31, 2026 | 137.98M |
| December 31, 2025 | 140.72M |
| September 30, 2025 | 144.20M |
| June 30, 2025 | 53.87M |
| March 31, 2025 | 55.09M |
| December 31, 2024 | 60.29M |
| September 30, 2024 | 6.070M |
| June 30, 2024 | 7.180M |
| March 31, 2024 | 8.912M |
| December 31, 2023 | 7.345M |
| September 30, 2023 | 8.593M |
| June 30, 2023 | 10.34M |
| March 31, 2023 | 11.83M |
| December 31, 2022 | 13.23M |
| September 30, 2022 | 14.44M |
| June 30, 2022 | 16.74M |
| March 31, 2022 | 18.07M |
| December 31, 2021 | 20.52M |
| September 30, 2021 | 22.52M |
| Date | Value |
|---|---|
| June 30, 2021 | 24.46M |
| March 31, 2021 | 25.91M |
| December 31, 2020 | 16.87M |
| September 30, 2020 | 18.16M |
| June 30, 2020 | 12.80M |
| March 31, 2020 | 12.84M |
| December 31, 2019 | 13.35M |
| September 30, 2019 | 5.109M |
| June 30, 2019 | 5.595M |
| March 31, 2019 | 6.354M |
| December 31, 2018 | 7.318M |
| September 30, 2018 | 7.888M |
| June 30, 2018 | 8.447M |
| March 31, 2018 | 9.148M |
| December 31, 2017 | 9.931M |
| September 30, 2017 | 10.60M |
| June 30, 2017 | 4.293M |
| March 31, 2017 | 9.931M |
| December 31, 2016 | 2.896M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Agenus, Inc. | 172.69M |
| Amgen, Inc. | 95.64B |
| Anika Therapeutics, Inc. | 183.47M |
| BioCryst Pharmaceuticals, Inc. | 557.85M |
| Imunon, Inc. | 14.99M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 4.124M |
| Shareholders Equity (Quarterly) | 130.86M |
| Debt to Equity Ratio | 0.0008 |
| Current Ratio | 33.56 |
| Net Debt Paydown Yield | 0.00% |